Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? | Breast Cancer Research | Full Text
Development of Zoledronic Acid-Based Nanoassemblies for Bone-Targeted Anticancer Therapy | ACS Biomaterials Science & Engineering
Cureus | Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment | Article
Zoledronic Acid–Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment | ACS Nano
Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library
![PDF] The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/02ae3788787adf6a230ad8aee9e0cf256fd0f00b/2-Figure1-1.png "PDF] The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. | Semantic Scholar")
PDF] The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. | Semantic Scholar
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions - ScienceDirect
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy | SpringerLink
Zoledronic acid | New Drug Approvals
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. | Semantic Scholar
Mechanism of action of denosumab compared to zoledronic acid. Notes:... | Download Scientific Diagram
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review | BMC Cancer | Full Text
Cancers | Free Full-Text | Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments
Zoledronic Acid–Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment | ACS Nano
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review | BMC Cancer | Full Text
Mechanism of action of denosumab compared to zoledronic acid. Notes:... | Download Scientific Diagram
ZOMETA (zoledronic acid) for Hypercalcemia of Malignancy and Bone Metastases - Cancer Therapy Advisor
Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer Results of the OPTIMIZE-2 trial – OncoPrescribe
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions - ScienceDirect
Cancers | Free Full-Text | Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer
Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug | Scientific Reports
Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways
Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma | Bentham Science
